Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Trial Profile

Phase I Study of Single Agent Pembrolizumab (MK-3475) in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma (KEYNOTE 001)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms KEYNOTE-001
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 06 Jun 2017 3 year overall survival results (Data cut off 1 sep 2016; n=550), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2017 Results (n=98) of secondary analysis assessing the effect of previous radiotherapy on progression free survival and overall survival published in the Lancet Oncology.
    • 12 Mar 2017 Results (n=315) of KEYNOTE-001,KEYNOTE-002, KEYNOTE-006 and one expanded acces phase II study assessing clinicopathological factors in PD-1 antibodies response published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top